Akuvio develops a new medical treatment for disc herniation that reduces inflammation and promotes resorption of the hernia. It has the potential to be the first effective, non-invasive, causal treatment for disc herniation, thus constituting a paradigm shift in the treatment of these patients. The treatment can be applied at home and is based on existing drugs that are currently used for other purposes.
The researchers have identified a potential way to use currently available immune suppressive compounds in the treatment of severe disc herniation. If successful this could offer more disc herniation patients a better treatment, at a lower cost for the health care system.
Impact: A better treatment at a lower cost for the health care systemGUV Contact: Jan Pilebjer